OBJECTIVE： To evaluate the effectiveness of Liuwei wuling tablets combined with entecavir in the treatment of chronic hepatitis B （CHB）， and to provide evidence-based reference in clinic. METHODS： Retrieved from Cochrane library， PubMed， Web of Science， CJFD， Wanfang database and VIP， randomized controlled trials （RCTs） about Liuwei wuling tablets combined with entecavir （trial group） vs. entecavir alone （control group） in the treatment of CHB were collected. Meta-analysis was conducted by using Rev Man 5.3 statistical software after data extraction and quality evaluation with Cochrane systematic evaluator manual 5.1.0. RESULTS： A total of 8 RCTs were included， involving 728 patients. Results of Meta-analysis showed that the levels of ALT [MD＝－16.67，95％CI（－19.83，－13.51），P＜0.001]， AST [MD＝－20.52，95％CI（－25.65，－15.39），P＜0.001] and TBIL [MD＝－5.85，95％CI（－11.31，－0.38），P＝0.04] in trial group were significantly lower than control group； clinical total response rate [RR＝1.23，95％CI（1.03，1.46），P＝0.02] and HBeAg negative conversion rate [RR＝1.26，95％CI（1.03，1.54）， P＝0.02] were significantly higher than control group， with statistical significance. There was no statistical significance in the rate of serum HBV DNA negative conversion [RR＝1.22，95％CI（0.99，1.52）， P＝0.07] between 2 groups. CONCLUSIONS： Compared with entecavir alone， Liuwei wuling tablets combined with entecavir in the treatment of CHB have better efficacy， can significantly improve the biochemical indexes of liver function in patients.